Photopharmics raises $6M for Parkinson’s light therapy device

Photopharmics has raised $6 million to complete a Phase 3 clinical trial of its light therapy device, Celeste, for Parkinson’s disease. The funds will also support efforts to prepare for regulatory submissions and product launch. About the Light for PD Trial The ongoing trial, known as Light for PD (NCT04453033), is based at the University of Rochester in New York. It aims to enroll 300 U.S. participants who have relatively good vision. So far, more than 200 individuals have joined. Participants are randomly assigned to use either Celeste or a sham device emitting non-therapeutic light. The study, which lasts six months, includes virtual clinic visits at the beginning, mid-point, and end to monitor changes in motor and nonmotor symptoms, as well as quality of life. What Is Celeste? Celeste is a tablet-sized, at-home device that uses specific wavelengths of light to stimulate photoreceptors in the eye. This is intended to help regulate circadian rhythms, which can affect sleep, energy levels, and symptom severity in people with Parkinson’s. The technology is designed to complement existing treatments. Users position the device to face them and use it for an hour each evening during regular activities like watching TV or reading. Earlier Research and Results A previous trial (NCT02175472) completed in 2016 showed that the Spectramax light therapy technology used in Celeste helped reduce disease severity and improve nonmotor symptoms and quality of life in Parkinson’s patients. Challenges and Accessibility The current study has faced some technical hurdles—particularly around remote consent and navigating the device software—but participants have been able to successfully use the device at home. A New Category of Care for Parkinson’s Kent Savage, CEO of Photopharmics, emphasized the innovation behind Celeste, stating: “With Celeste, we’re not just adding a new product—we’re building an entirely new category of care for Parkinson’s.” He highlighted the urgent need for new solutions, with over 11 million people worldwide living with Parkinson’s and limited breakthrough treatments in recent decades. Next Steps The new investment will help Photopharmics finish the trial, build strategic partnerships, and prepare submissions for regulatory approval, including with the U.S. Food and Drug Administration. Savage added: “This funding gives us the runway we need to complete our clinical program and ensure the best possible outcomes for patients.” Trial completion is expected in the coming months.